- Triangle Pharmaceuticals, founded in the USA in 1995 by former staff at the UK company Wellcome before its takeover by Glaxo, has completed an $18.5 million second-round private equity financing. Proceeds will be used to advance programs to develop novel therapeutics for serious viral diseases and cancer. "Since our founding in July 1995, we have built a portfolio of six novel drug candidates which are progressing well through the drug development process," commented David Barry, the firm's chairman and chief executive.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze